European Medicines Agency - Withdrawals of Application - Medicinal Products for Human Use - Cerepro

CEREPRO
International Nonproprietary Name:
adenovirus-mediated Herpes Simplex Virus-thymidine kinase gene
Procedure No. EMEA/H/C/694
Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted.
This should be read in conjunction with the “Question and Answer” document on the withdrawal of
the application: the Assessment Report may not include all available information on the product if the CHMP assessment of the latest submitted information was still ongoing at the time of the withdrawal of the application.

abrir aquí para acceder a los documentos individuales:
European Medicines Agency - Withdrawals of Application - Medicinal Products for Human Use - Cerepro